New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.
27 Oct 02:28 · News-Medical